REGN

Regeneron Pharmaceuticals 株価情報 (NASDAQ: REGN)

最新ニュース Regeneron Pharmaceuticals (NASDAQ:REGN) 株価情報

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals Inc

REGENERON PHARMACEUTICALS ORD

Regnum Corp

Just two weeks ago, Upstream Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of <a href="https://www.benzinga.com/pressreleases/24/10/g41344387/upstream-bio-announces-closing-of-293-million-upsized-initial-public-offering-including-full-exerc" target="_blank" rel="noreferrer noopener">approximately $293 million</a>.
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases with an initial focus on severe respiratory disorders.
<ul>
<li>Piper Sandler initiated coverage on Upstream Bio with an Overweight rating and a <a href="https://www.benzinga.com/quote/UPB/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $75</a>.</li>
<li>William Blair has also initiated coverage of Upstream Bio with an Outperform rating </li>
</ul>
Piper Sandler noted the company&#8217;s lead program, verekitug, has a differentiated mechanism of action that targets the TSLP receptor vs. ligand.
The TSLP ligand has been de-risked by AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) / Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Tezspire&#8217;s 2021 approval in severe asthma, the analyst says. It represents a rapidly growing biologic market opportunity of over $7.5 billion.
Piper analyst writes, &#8220;verekitug&#8217;s key advantage is its durability given its high potency, enabling Q12W dosing and potentially up to Q24W dosing, which is significantly lower compared to other biologics such as Tezspire (Q4W dosing) and Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) / Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (Q2W dosing).
William Blair also based its rating on the blockbuster potential of verekitug in large indications, including asthma and chronic obstructive pulmonary disease (COPD).
&#8220;The analyst writes that &#8220;Verekitug has the potential to deliver differentiated efficacy and longer dosing intervals than currently approved biologics for the treatment of asthma, most notably the TSLP antibody Tezspire, which targets the ligand.
William Blair writes that demonstrating clinical efficacy at least comparable to Tezspire, with dosing intervals of every three to six months, could position the therapy as a blockbuster, aligning with patient preferences for fewer doses.
However, early preclinical and clinical data for verekitug indicate a potential for even greater efficacy than Tezspire, which could exceed current baseline expectations.
Price Action: Upstream Bio stock is up 12.5% at $28.30 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41753290/ferrari-slows-down-q3-shipment-drop-hits-the-brakes-on-stock-growth" target="_blank" rel="noreferrer noopener">Ferrari Slows Down, Q3 Shipment Drop Hits the Brakes On Stock Growth</a></li>
</ul>

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

AMGN

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Investors with a lot of money to spend have taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for Regeneron Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 60%, bearish.
Out of all of the special options we uncovered, 16 are puts, for a total amount of $5,066,701, and 4 are calls, for a total amount of $205,030.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $420.0 to $1120.0 for Regeneron Pharmaceuticals over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Regeneron Pharmaceuticals's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Regeneron Pharmaceuticals's substantial trades, within a strike price spectrum from $420.0 to $1120.0 over the preceding 30 days.
<h3>Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730750439_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$233.0</td>
<td>$224.0</td>
<td>$232.48</td>
<td>$1060.00</td>
<td>$2.0M</td>
<td style="text-align: right;">95</td>
<td style="text-align: right;">91</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$210.0</td>
<td>$203.9</td>
<td>$209.06</td>
<td>$1040.00</td>
<td>$837.4K</td>
<td style="text-align: right;">98</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$99.0</td>
<td>$90.8</td>
<td>$97.52</td>
<td>$930.00</td>
<td>$485.0K</td>
<td style="text-align: right;">99</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$190.0</td>
<td>$181.4</td>
<td>$189.9</td>
<td>$1020.00</td>
<td>$379.9K</td>
<td style="text-align: right;">126</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$69.7</td>
<td>$64.0</td>
<td>$67.8</td>
<td>$880.00</td>
<td>$271.2K</td>
<td style="text-align: right;">49</td>
<td style="text-align: right;">40</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Having examined the options trading patterns of Regeneron Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Regeneron Pharmaceuticals's Current Market Status</h3>
<ul>
<li>Trading volume stands at 391,366, with REGN's price down by -1.56%, positioned at $830.46.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 88 days.</li>
</ul>
<h3>What The Experts Say On Regeneron Pharmaceuticals</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $1138.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Regeneron Pharmaceuticals, targeting a price of $1150. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Regeneron Pharmaceuticals with a target price of $1080. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Regeneron Pharmaceuticals, targeting a price of $1215. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Regeneron Pharmaceuticals with a target price of $1065. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Regeneron Pharmaceuticals, targeting a price of $1184. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

This Is What Whales Are Betting On Regeneron Pharmaceuticals

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1235 to $1184.

Price Target

Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1184

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and lowers the price target from $1260 to $1215.

RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1215

Barclays analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1080 to $1065.

Barclays Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1065

BMO Capital analyst Evan David Seigerman maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and lowers the price target from $1300 to $1190.

BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1190

Truist Securities analyst Srikripa Devarakonda maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and lowers the price target from $1137 to $1126.

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $1126

Piper Sandler analyst Christopher Raymond maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1242 to $1195.

Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1195

On Thursday,&nbsp;Regeneron Pharmaceuticals&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)&nbsp;reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $11.69</a>.
The company reported sales of $3.72 billion, up 11%, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41647880/regeneron-reports-third-quarter-2024-financial-and-operating-results" rel="noreferrer noopener">consensus of $3.67 billion</a>.
&#8220;Regeneron&nbsp;had a strong third quarter marked by 11% revenue growth. We continued to deepen the impact of our commercialized medicines this quarter, with ongoing leadership for our retinal franchise, expanded global reach of Libtayo, and notable growth from Dupixent,&#8221; said&nbsp;Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of&nbsp;Regeneron.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41208078/regeneron-chief-flags-health-risks-with-popular-weight-loss-medications-like-ozempic-says-company" rel="noreferrer noopener">Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs</a>
&#8220;Our strong third quarter financial performance was highlighted by double-digit revenue growth and continued investment in our growing pipeline,&#8221; said Christopher Fenimore, Senior Vice President, Finance and Chief Financial Officer of Regeneron.
Third quarter 2024 U.S. net sales for Eylea HD&nbsp;and Eylea&nbsp;increased 3% versus third quarter 2023 to $1.54&nbsp;billion, including $392 million from Eylea HD.
A lower net selling price adversely impacted the net product sales of EYLEA in the third quarter of 2024.
Libtayo&nbsp;global net sales increased by 25% to $289 million.
Sanofi SA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) collaboration revenue increased from $1.06 billion to $1.26 billion.
The company said its obesity clinical program is now enrolling.
In its earnings <a target="_blank" href="https://investor.regeneron.com/static-files/4ac68b22-7abe-4d1f-a15a-2a9b739cc935" rel="noreferrer noopener">presentation</a>, Regeneron said Phase 2 study to investigate if addition of trevogrumab (anti-myostatin) to Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide with and without garetosmab (antiactivin A) improves the quality of weight loss and/or improves maintenance of weight loss post semaglutide discontinuation.
Safety and tolerability data for high-dose trevogrumab in healthy volunteers showed no new safety signals.
The company is on track to complete enrollment by year-end 2024; results for both primary endpoints are expected in 2H25.
Price Action: REGN stock is down 10.7% at $824.28 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41656437/cignas-q3-profit-beats-street-on-strong-demand-for-pharmacy-benefit-managements-specialty-drugs-new" target="_blank" rel="noreferrer noopener">Cigna&#8217;s Q3 Profit Beats Street On Strong Demand For Pharmacy Benefit Management&#8217;s Specialty Drugs, New Clients</a></li>
</ul>

Earnings

Large Cap

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?

Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices <a href="https://www.benzinga.com/markets">in nearly two months.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) plummeted over 5% by midday trading in New York, on track for its worst session in two years. Although the company surpassed earnings estimates, it forecasted slower growth in its Azure cloud business, dampening future revenue expectations.
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) also declined by over 4% despite a strong quarterly performance, as the social media giant projected &#8220;significant&#8221; capital expenditure growth next year, particularly for AI infrastructure.
The elite &#8220;Magnificent Seven&#8221; tech group shed nearly $500 billion in market capitalization within a single day after reaching a record high of $16.8 trillion. Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are set to report earnings after the market close.
In economic news, inflation sent mixed signals for September. The Personal Consumption Expenditures (PCE) price index slowed as expected to 2.1% annually, while the Fed's preferred inflation measure, the core PCE price index, remained at 2.7% year over year, slightly <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41658542/fed-interest-rate-cuts-expected-but-economists-warn-of-bumpy-course-in-this-last-">above the expected 2.6%.</a>
The S&amp;P 500 dropped 1.4%, and the tech-heavy Nasdaq 100 slid 2.2%, both tracking their worst session since Sept. 6. The CBOE Volatility Index (VIX) surged 12%.
Risk aversion also weighed on commodities, with gold prices dropping 1.7%, marking their worst day since July, and silver plunging 3% after a 2% decline on Wednesday. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) slid 2.4%, and crypto-related stocks suffered significant losses. Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) tumbled over 10% on disappointing earnings, eyeing its worst day since May.
<h3 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,832.30</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,213.10</td>
<td>-0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,729.43</td>
<td>-1.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,943.07</td>
<td>-2.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:20 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 1.5% to $571.51.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.8% to $418.60.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) tumbled 2.2% to $485.78. </li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.7% to $219.65.</li>
<li>The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, rising 1.4%. The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 2.4%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
Stocks reacting to corporate earnings were: 
<ul>
<li>Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), up over 5%, </li>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), up 1.7%,</li>
<li>Starbucks Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NYSE">SBUX</a>), down 0.6%, </li>
<li>eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>), down over 8%, </li>
<li>MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), up 1.9%,</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), up 24%,</li>
<li>Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), down 1.8%, </li>
<li>Merck &amp; Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), down 2.8%,</li>
<li>Linde plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>), down 2.9%, </li>
<li>Comcast Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), up 2.9%, </li>
<li>Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), down over 11%, </li>
<li>Eaton Corp. plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>), down 5%, </li>
<li>ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), up 6%, </li>
<li>Bristo-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), up 3.3%, </li>
<li>Southern Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>), up 2.2%, </li>
<li>Altria Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>), up 7.6%, </li>
<li>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), down 9%, </li>
<li>The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), up 3%, </li>
<li>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>), up over 9%. </li>
<li>Cheniere Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>), up over 5%. </li>
</ul>
Large-cap companies slated to report their earnings after the close include Apple Inc, Amazon.com Inc, Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), Atlassian Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) and Coterra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41658754/microsoft-in-major-growth-mode-not-slowing-down-4-analysts-see-strong-azure-demand-">Microsoft &#8216;In Major Growth Mode,&#8217; Not Slowing Down: 4 Analysts See Strong Azure Demand, AI Monetization Efforts</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

Tech

ETFs

$BTC

AAPL

AMZN

BKNG

CMCSA

COIN

CTRA

CVNA

SPDR Dow Jones Industrial Average ETF Trust

EBAY

INTC

MSFT

MSTR

NCLH

SBUX

TEAM

UBER

Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?

WIIM

Regeneron shares are trading lower following Q3 earnings.

Guidance

Regeneron Sees FY24 Non-GAAP Gross Margin On Net Product Sales Approximately 89%, Unchanged From Prior

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) reported quarterly earnings of $12.46 per share which beat the analyst consensus estimate of $11.69 by 6.59 percent. The company reported quarterly sales of $3.720 billion which beat the analyst consensus estimate of $3.670 billion by 1.36 percent. This is a 10.62 percent increase over sales of $3.363 billion the same period last year.

Earnings Beats

Regeneron Pharmaceuticals Q3 2024 Adj. EPS $12.46 Beats $11.69 Estimate, Sales $3.720B Beat $3.670B Estimate

On Tuesday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41598312/novartis-q3-earnings-beats-expectations-on-strong-sales-from-key-drugs-lifts-2024-outlook" rel="noreferrer noopener">consensus of $12.76 billion</a>.
Guidance: Novartis also raised its 2024 full-year guidance again this year.
In a statement, Novartis said it expects full-year core operating income to grow by a &#8220;high teens&#8221; percentage, compared with previous guidance of a &#8220;mid-to-high teens&#8221; percentage.
Novartis forecasts full-year sales growth in the low double digits, having previously guided for high-single to low-double-digit growth.
Pelabresib filing was further delayed, triggering a $800 million impairment charge related to the $2.9 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38497134/morphosys-says-novartis-deal-progressing-steadily-despite-safety-concerns-over-bone-marrow-cancer" rel="noreferrer noopener">acquisition of MorphoSys</a>.
Earlier this year, MorphoSys faced&nbsp;a burgeoning safety concern surrounding&nbsp;pelabresib.
Goldman Sachs notes that MorphoSys-related impairment charge is somewhat underwhelming, raising doubts about the company&#8217;s M&amp;A strategy.
Truist notes that Novartis is concentrating on preparing the market for the PSMAFore label, which is expected to triple its addressable market.
They also pointed out that growth opportunities in China and Japan, and metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease, could push Pluvicto&#8217;s sales well above the projected $2 billion peak.
The company is committed to maximizing the potential of Pluvicto and its radioligand therapy (RLT) portfolio.
For other radiopharmaceutical companies targeting PSMA, entering this market may become more challenging.
A crucial question remains regarding the standards that must be met to compete with more effective radioligand products. This context relates to companies such as Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which have RLT products in their pipelines, as well as smaller companies, including Y-mAbs Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) and Perspective Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NASDAQ">CATX</a>).
Novartis highlighted continued strong growth and momentum and sees room to grow the market size for B-cell inhibition in multiple sclerosis, relating Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Truist highlights Novartis&#8217; strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few larger bolt-on acquisitions.
A Truist analyst indicated that they will be monitoring how the adoption of Leqvio may affect Amgen Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Repatha and Regeneron Pharmaceuticals Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Praluent. Meanwhile, Novartis has reported that the launch is advancing smoothly, and Leqvio continues to grow, outpacing the overall market as per the management.
Novartis&#8217; Cosentyx witnessed strong uptake and continued brand growth driven by hidradenitis suppurativa expansion, and the market opportunity can accommodate several players, Abbvie Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NASDAQ">ABBV</a>), Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), and Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>).
Price Action: NVS stock is down 0.48% at $110.00 at last check Wednesday.
Photo by Taljat David via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41629995/orthopedic-implant-maker-zimmer-biomet-reports-better-than-expected-q3-earnings-updates-annual-fore" target="_blank" rel="noreferrer noopener">Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts</a></li>
</ul>

ABBV

BIIB

CATX

INCY

KYMR

YMAB

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

EyePoint Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) stock is trading higher on Monday after the company revealed interim 16-week data from the ongoing Phase 2 VERONA trial of Duravyu for patients with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41569697/eyepoint-pharmaceuticals-announces-positive-interim-16-week-data-for-ongoing-phase-2-verona-clinic" rel="noreferrer noopener">diabetic macular edema (DME)</a>.
Duravyu is an investigational sustained-delivery therapy that delivers patent-protected vorolanib, a selective tyrosine kinase inhibitor formulated in bioerodible Durasert E.
Duravyu 2.7mg demonstrated an early, sustained, and clinically meaningful improvement in best-corrected visual acuity (BCVA) and anatomical control versus the Regeneron Pharmaceutical Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Eylea (aflibercept) control arm.
A favorable safety and tolerability profile continued for both Duravyu arms.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38641939/why-is-eyepoint-pharmaceuticals-stock-plummeting-on-monday" rel="noreferrer noopener">Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?</a>
The 2.7mg dose is also being evaluated in the Phase 3 pivotal trials for wet age-related macular degeneration&nbsp;(wet AMD).
The company expects to report the full topline results in the first quarter of 2025.
Duravyu 2.7mg demonstrated an early and sustained improvement in BCVA and CST (central subfield thickness) as measured by optical coherence tomography (OCT).
<ul>
<li>BCVA improved +8.9 letters versus +3.2 letters for aflibercept control compared to baseline.</li>
<li>CST improved 68.1 microns versus 30.5 microns for aflibercept control compared to baseline.</li>
</ul>
Visual and anatomical gains were observed at Week 4, demonstrating the immediate bioavailability of DURAVYU.
The positive trend in BCVA and anatomy continued for patients who reached the Week 24 visit.
Continued to show encouraging safety and tolerability profile with no Duravyu-related ocular or systemic serious adverse events.
At 16 weeks, 2% of eyes in the Duravyu 2.7 mg arm were supplement-free, compared to 50% in the aflibercept control arm.
Price Action: EYPT stock is up 36.7% at $12.99&nbsp;at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41578225/why-is-nao-cap-neurology-focused-autonomix-medical-stock-trading-higher-on-monday" target="_blank" rel="noreferrer noopener">Why Is Nao-Cap Neurology Focused Autonomix Medical Stock Trading Higher On Monday?</a></li>
</ul>

EYPT

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss

On Friday, Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), which will be presented at the Fall <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41540619/lillys-ebglyss-lebrikizumab-lbkz-demonstrated-meaningful-improvement-in-skin-clearance-and-itch-re" rel="noreferrer noopener">Clinical Dermatology Conference</a>.
The results show that Ebglyss improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) / Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent (dupilumab).
The study&#8217;s primary endpoint was measured by at least a 75% improvement in the Eczema Area and Severity Index (EASI-75) score at 16 weeks, which evaluates the extent and severity of the skin disease.
Secondary endpoints at 16 and 24 weeks included Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin with a reduction of at least two points from baseline and at least a four-point improvement in Pruritus NRS from baseline.
With Ebglyss, 57% of patients in Week 16 and 60% in Week 24 who had previously been treated with dupilumab achieved EASI-75.
In addition, 46% of patients who were inadequate responders to dupilumab achieved EASI-75 response with Ebglyss at Week 16.
53% and 62% of ADapt patients who discontinued dupilumab and began treatment with Ebglyss also experienced itch relief (Pruritus NRS) with at least a four-point improvement from baseline at Week 16 and Week 24, respectively.
Patients in this study saw improvements in difficult-to-treat areas when treated with Ebglyss.
52% treated with Ebglyss saw clear or almost clear face dermatitis at Week 24.
Among patients with moderate-to-severe hand dermatitis at baseline, the modified total lesion-symptom score, which measures the extent and severity of hand dermatitis, decreased by 75 percent at Week 24.
Less than 6% of patients treated with Ebglyss experienced an adverse event that led to treatment discontinuation.
Last month, the FDA approved Ebglyss, a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40884197/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss" rel="noreferrer noopener">topical prescription therapies</a>.
Ebglyss was also approved in the European Union in 2023 and Japan in January 2024, with additional markets expected later this year.
Price Action: LLY stock is up 0.32% at $894.15 at last check Friday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41551304/bkvs-integrated-operations-offer-value-analyst-highlights-unique-closed-loop-system" target="_blank" rel="noreferrer noopener">BKV&#8217;s Integrated Operations Offer Value, Analyst Highlights Unique &#8216;Closed-Loop&#8217; System And Growth Prospects</a></li>
</ul>

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent

RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and maintains $1260 price target.

Reiteration

RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1260 Price Target

Evercore ISI Group analyst Cory Kasimov maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and lowers the price target from $1250 to $1175.

Evercore ISI Group Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1175

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 15 years by 19.22% on an annualized basis producing an average annual return of 31.38%. Currently, Regeneron Pharmaceuticals has a market capitalization of $103.78 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $5,797.23 today based on a price of $941.47 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729780218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today

JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1200 to $1150.

JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1150

Morgan Stanley lowered the firm's price target on Regeneron (REGN) to $1,184 from $1,235 and keeps an Overweight rating on the shares following a Q...

Regeneron selloff 'overdone' with pipeline catalysts coming, says Morgan Stanley

Truist lowered the firm's price target on Regeneron (REGN) to $1,126 from $1,137 and keeps a Buy rating on the shares after its Q3 results. Investo...

Regeneron price target lowered to $1,126 from $1,137 at Truist

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming. Therefore, it could be wise to invest in solid biotech stocks Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD) for substantial returns. Read more... With the rapidly increasing drug discovery and sequential approvals, surging R&amp;D initiatives, coupled with recent Fed rate cuts likely to encourage funding and investing, the biotech industry is positioned to experience solid growth. Also, advancements in technologies are swiftly accelerating the prospects of the market.
Given the industry's positive prospects, it could be ideal to invest in fundamentally strong biotech stocks Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>), Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>) with promising pipelines.
The role of the biotech industry in today's generation is continuously expanding with increasing incidents of chronic diseases and conditions, rising demand for personalized medicine, and rapid acceleration in drug discovery fueled by the application of cutting-edge technologies like Artificial Intelligence (AI).
Over 38 new drugs have been approved by the <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">U.S. Food and Drug Administration (FDA)</a> this year to address conditions such as schizophrenia, urinary tract infections, breast cancer, and lung cancer and to treat Alzheimer's disease. The increased drug discovery and intense research and development (R&amp;D) will potentially accelerate further breakthroughs.
Also, the biotech industry is poised to capitalize on the <a href="https://www.biopharmadive.com/news/biotech-interest-rates-impact-startups-venture-capital/727479/#:~:text=During%20the%20Fed's%20recent%20tightening,for%20those%20companies%20already%20public.">Federal Reserve's recent interest rate cut</a>. The rate cut resulted in lower borrowing costs. It could potentially lead to increased investment and improve the market sentiment.
Moreover, the global biotechnology market is expected to reach $4.61 trillion by 2034, growing at a <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20global%20biotechnology%20market%20size%20accounted%20for%20USD%201.55%20trillion%20in%202024%20and%20is%20expected%20to%20reach%20around%20USD%204.61%20trillion%20by%202034%2C%20expanding%20at%20a%20CAGR%20of%2011.5%25%20from%202024%20to%202034.">CAGR of 11.5%</a>. The U.S. biotechnology market is predicted to be worth around $830.31 billion by 2034. Strong R&amp;D initiatives, increasing drug approvals, and improvement of healthcare infrastructure are driving the market growth.
Further, the increasing application of generative AI in Biotech to design novel molecules, proteins, and drugs is revolutionizing the drug discovery and development processes. With this accelerating innovation and drug candidate identification, the <a href="https://www.pharmiweb.com/press-release/2024-04-15/generative-ai-in-biotech-market-to-skyrocket-to-usd-472-million-by-2032-marketresearchbiz#:~:text=Generative%20AI%20in%20Biotech%20utilizes,innovation%20and%20drug%20candidate%20identification.">generative AI in the biotech market</a> is expected to grow to $472 million by 2032 at a CAGR of 24.9%.
Considering the encouraging economic trends, let's delve into the fundamentals of the top three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>)
AMGN discovers, develops, manufactures, and delivers human therapeutics globally. The company's principal products include Enbrel, Otezla, Prolia, XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, and KRYSTEXXA.
On August 20, AMGN announced the availability of Otezla&#xAE; (apremilast) in the U.S. for pediatric use. The U.S. FDA approved Otezla earlier this year for treating moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy.
This is currently the first and only FDA-approved oral medication for children and adolescents ages 6-17 with moderate to severe plaque psoriasis.
On June 14, AMGN announced that the FDA approved BLINCYTO to treat adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia in the consolidation phase.
BLINCYTO is the first and only globally approved Bispecific T-cell Engager (BiTE&#xAE;) immuno-oncology therapy that targets CD19 surface antigens on B cells. It demonstrated superior overall survival versus chemotherapy alone.
During the third quarter that ended September 30, 2024, AMGN reported total revenues of $8.50 billion, up 23.2% year-over-over. Its non-GAAP <a href="https://www.investopedia.com/terms/o/operatingincome.asp">operating income</a> grew 18.8% from the year-ago value to $4.04 billion. The company's non-GAAP net income and EPS amounted to $3.02 billion and $5.58, indicating increases of 13.4% and 12.5% from the prior year's quarter, respectively.
Furthermore, the company's free cash flow rose 32% from the prior year period to $3.30 billion.
For the full year 2024, AMGN expects total revenues in the range of $33 billion to $33.80 billion and non-GAAP EPS in the range of $19.20 to $20.00.
Analysts expect AMGN's revenue and EPS for the fourth quarter (ending December 2024) to grow 8.2% and 8.3% year-over-year to $8.87 billion and $5.10, respectively. Also, the company topped the consensus EPS and revenue estimates in three of the four trailing quarters.
Shares of AMGN have surged 16.9% over the past six months and 25.2% over the past year to close the last trading session at $320.16.
AMGN's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
AMGN has a B grade for Quality. It is ranked #25 out of 329 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
In addition to the POWR Ratings we've stated above, we also have AMGN ratings for Value, Momentum, Stability, Growth, and Sentiment. Get all AMGN ratings <a href="https://stocknews.com/stock/AMGN/">here</a>.
Stock #2: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
On October 18, REGN announced positive three-year data for EYLEA HD&#xAE; (aflibercept) Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema (DME). Patients who switched to EYLEA HD experienced substantially slower fluid reaccumulation.
The phase 3 PHOTON trial continued to demonstrate that EYLEA HD can safely provide meaningful and lasting vision and anatomical benefits for people living with diabetic macular edema and can prove to be revolutionary for the patients.
On September 27, REGN and Sanofi received FDA approval for Dupixent&#xAE; (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. This marked Dupixent as the first biological medicine approved in the U.S. to treat these patients.
During the third quarter that ended September 30, 2024, REGN's revenues increased 10.6% year-over-year to $3.72 billion. Its income from operations increased 6.2% from the year-ago value to $1.18 billion. The company's non-GAAP net income came in at $1.46 billion or $12.46 per share, indicating growth of 10% and 7.5% year-over-year, respectively.
Street expects REGN's revenue for the first quarter (ending March 2025) to increase 16.4% year-over-year to $3.66 billion, while its EPS is expected to grow 19.7% year-over-year to $11.43, respectively. Furthermore, the company surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.
REGN's stock has gained 7.5% over the past year to close the last trading session at $838.20.
REGN's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
The stock has a B grade for Value and Quality. REGN is ranked #9 among 329 stocks in the Biotech industry.
<a href="https://stocknews.com/stock/REGN/">Click here</a> to access REGN's ratings for Momentum, Growth, Stability, and Sentiment.
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs internationally. The company provides products like Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla.
On October 31, GILD and AbTherx, a biotechnology company with innovative technologies, expanded their previous agreement to develop novel antibody discovery technologies and discover therapeutic antibodies for Gilead-selected targets. The expanded partnership will include additional technologies and multiple new research programs.
On October 02, GILD entered into a non-exclusive, royalty-free voluntary licensing agreement with Hetero, India's leading pharmaceutical company, to manufacture and distribute lenacapavir in 120 countries. The strategic agreement is in line with GILD's vision and will broaden access to lenacapavir, the innovative HIV treatment used in combination with other antiretroviral.
The partnership will aid the efforts to prevent HIV through pre-exposure prophylaxis (PrEP).
During the second quarter that ended June 30, 2024, GILD's total revenues were up 5.4% year-over-year to $6.95 billion, and its operating income grew 58.8% from the prior year quarter to $2.64 billion. Also, the company's non-GAAP net income and EPS totaled $2.52 billion and $2.01, up 49.2% and 50% from the prior year's quarter, respectively.
As per the company's full-year guidance, GILD projects product sales to range between $27.10 billion and $27.50 billion. It also expects non-GAAP EPS to be between $3.60 and $3.90, an increase from the previous $3.45 to $3.85 guidance.
Street expects GILD's revenue for the fiscal year (ending December 2025) to increase 1.1% year-over-year to $28.05 billion, and its EPS for the same period is expected to grow 91.9% year-over-year to $7.26. Also, the company surpassed the consensus revenue estimates in all trailing four quarters, which is impressive.
GILD's stock has gained 36.2% over the past six months and 13.1% over the past year to close the last trading session at $88.82.
GILD's POWR Ratings reflect its robust outlook. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
The stock has an A grade for Value. It also has a B grade for Sentiment and Quality. Within the same industry, GILD is ranked #3 among 329 stocks.
<a href="https://stocknews.com/stock/GILD/">Click here</a> to access additional ratings of GILD for Momentum, Growth, and Stability.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
AMGN shares were unchanged in after-hours trading Friday. Year-to-date, AMGN has gained 13.28%, versus a 21.27% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/amgn-gild-regn-3-biotechnology-stocks-with-promising-pipelines/>3 Biotechnology Stocks With Promising Pipelines</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotechnology Stocks With Promising Pipelines

S&P 500 Ends 5-Month Rally With October Downturn

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $1,...

TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN)

A bit of earnings and election jitters roiled the market last week reordering  the leaderboard in biopharma stocks.

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required

Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Madrigal Pharmaceuticals (MDGL – Research Report), Travere Therap...

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Travere Therapeutics (TVTX) and Regeneron (REGN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Argenx Se (ARGX – Research Report), Regeneron (REGN ...

Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Regeneron (REGN)

ALNY

ARGX

BAPR

BAUG

BJUL

BJUN

BMAR

BMAY

BOCT

BUFF

CATH

CSTNL

EFIV

GILD

HIBL

HIBS

INSM

IONS

MDGL

NOBL

NTLA

NVDA

PAPR

PAUG

PJAN

PJUN

PUTW

QDIV

QRVO

QVML

RSPT

SNPE

SPDN

SPDV

SPGP

SPHB

SPHD

SPHQ

SPLG

SPLV

SPMO

SPMV

SPUS

SPUU

SPVM

SPVU

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SSPY

TVTX

UAUG

UJAN

UMAR

UMAY

UOCT

UPRO

USMC

VOOG

VOOV

VRTX

XRLV

XYLD

XYLG

Screenshot 2024-09-10 at 8.49.39 PM

MAIA

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Press Releases

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI

Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

Regeneron Reports Third Quarter 2024 Financial and Operating Results

Comments

Regeneron Pharmaceuticals

ニュース

最新ニュース Regeneron Pharmaceuticals (NASDAQ:REGN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル